Muss, H B <br/><br/>
Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Aug 1994 
 - 1630-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1994.12.8.1630  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Bone Neoplasms--drug therapy<br/>Breast Neoplasms--drug therapy<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Liver Neoplasms--drug therapy<br/>Medroxyprogesterone Acetate--administration & dosage<br/>Middle Aged<br/>Prospective Studies<br/>Regression Analysis<br/>Soft Tissue Neoplasms--drug therapy<br/>Survival Analysis<br/>Tamoxifen--administration & dosage